The current financial score of Mirum Pharmaceuticals Inc is 6.58. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 185.72M, representing a year-over-year increase of 39.63%, while its net profit experienced a year-over-year increase of 1503.30%.
The current valuation score of Mirum Pharmaceuticals Inc is 9.66. Its current P/E ratio is -6.90, which is -30.58% below the recent high of -4.79 and -3330.10% above the recent low of -236.52.
The current earnings forecast score of Mirum Pharmaceuticals Inc is 8.86. The average price target is 157.42, with a high of 202.00 and a low of 126.00.
The current price momentum score of Mirum Pharmaceuticals Inc is 4.63. Currently, the stock price is trading between the resistance level at 102.34 and the support level at 81.72, making it suitable for range-bound swing trading.
The current institutional shareholding score of Mirum Pharmaceuticals Inc is 10.00. The latest institutional shareholding proportion is 111.53%, representing a quarter-over-quarter decrease of 3.46%.
The current risk assessment score of Mirum Pharmaceuticals Inc is 6.48. The company's beta value is 0.50. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.